文献速递神经儿科影像MR

T2-FLAIR错配:儿童MYB/MYBL1改变弥漫性星形细胞瘤或血管中心性胶质瘤的影像生物标志物

T2-FLAIR Mismatch: An Imaging Biomarker for Children's MYB/MYBL1-Altered Diffuse Astrocytoma or Angiocentric Glioma.
PubMed 文献 · AJNR Am J Neuroradiol · 2024-06-07

本研究评估儿童IDH突变型星形细胞瘤与MYB/MYBL1改变低级别肿瘤中T2-FLAIR错配的诊断价值,并分析其与组织学微囊的关系。19例患儿中,错配在IDH突变组占38%(3例),在MYB/MYBL1改变组占73%(8例);错配与微囊或细胞间隙增大均无相关性。结论认为儿童中错配更多见于MYB/MYBL1改变肿瘤,且与成人IDH突变星形细胞瘤不同,未见与微囊改变相关。

要点

  • 儿童MYB/MYBL1改变肿瘤中T2-FLAIR错配出现率(73%)高于IDH突变星形细胞瘤(38%)。
  • 儿童IDH突变星形细胞瘤中错配与微囊或细胞间隙增大无相关性(P=.38、P=.56)。
  • 儿童MYB/MYBL1改变肿瘤中错配与微囊或细胞间隙增大亦无相关性(P=.36、P=.90)。

核心结论

  • 儿童中T2-FLAIR错配更多见于MYB/MYBL1改变肿瘤而非IDH突变星形细胞瘤,且与肿瘤组织微囊改变无相关性,挑战了微囊和/或细胞间隙增大解释错配的假说。

研究设计与样本

  • 在Princess Máxima儿童肿瘤中心与Utrecht大学医学中心2012年1月至2023年1月间,评估所有组织分子诊断为IDH突变星形细胞瘤、MYB/MYBL1改变弥漫性星形细胞瘤或血管中心性胶质瘤的儿童患者MR影像,并组织学评估肿瘤内微囊。

关键影像表现/征象

  • 19例患儿中,IDH突变星形细胞瘤8例,MYB/MYBL1改变肿瘤11例(其中MYB或MYBL1改变弥漫性星形细胞瘤8例,血管中心性胶质瘤3例)。
  • T2-FLAIR错配共11例,IDH突变组3例(38%),MYB/MYBL1改变组8例(73%)。

诊断标准与关键数值

  • T2-FLAIR错配在IDH突变星形细胞瘤组出现3/8(38%),在MYB/MYBL1改变肿瘤组出现8/11(73%)。
  • 错配与微囊在IDH突变星形细胞瘤组无相关性(P=.38),与细胞间隙增大亦无相关性(P=.56)。
  • 错配与微囊在MYB/MYBL1改变肿瘤组无相关性(P=.36),与细胞间隙增大亦无相关性(P=.90)。

临床应用与阅片要点

  • 儿童低级别胶质瘤出现T2-FLAIR错配时,需考虑MYB/MYBL1改变肿瘤可能,其出现率高于IDH突变星形细胞瘤。
  • 儿童中错配与组织学微囊或细胞间隙增大无相关性,阅片时不应以微囊改变作为错配的影像-病理对应依据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: T2-FLAIR mismatch is a highly specific imaging biomarker of IDH-mutant diffuse astrocytoma in adults. It has however also been described in MYB/MYBL1-altered low grade tumors. Our aim was to assess the diagnostic power of the T2-FLAIR mismatch in IDH-mutant astrocytoma and MYB/MYBL1-altered low-grade tumors in children and correlate this mismatch with histology.

MATERIALS AND METHODS: We evaluated MR imaging examinations of all pediatric patients, performed at the Princess Máxima Center for Pediatric Oncology and the University Medical Center Utrecht between January 2012 and January 2023, with the histomolecular diagnosis of IDH-mutant astrocytoma, diffuse astrocytoma MYB/MYBL1-altered, or angiocentric glioma, and the presence of T2-FLAIR mismatch was assessed. Histologically, the presence of microcysts in the tumor (a phenomenon suggested to be correlated with T2-FLAIR mismatch in IDH-mutant astrocytomas in adults) was evaluated.

RESULTS: Nineteen pediatric patients were diagnosed with either IDH-mutant astrocytoma (n = 8) or MYB/MYBL1-altered tumor (n = 11: diffuse astrocytoma, MYB- or MYBL1-altered n = 8; or angiocentric glioma n = 3). T2-FLAIR mismatch was present in 11 patients, 3 (38%) in the IDH-mutant group and 8 (73%) in the MYB/MYBL1 group. No correlation was found between T2-FLAIR mismatch and the presence of microcysts or an enlarged intercellular space in either IDH-mutant astrocytoma (P = .38 and P = .56, respectively) or MYB/MYBL1-altered tumors (P = .36 and P = .90, respectively).

CONCLUSIONS: In our pediatric population, T2-FLAIR mismatch was more often found in MYB/MYBL1-altered tumors than in IDH-mutant astrocytomas. In contrast to what has been reported for IDH-mutant astrocytomas in adults, no correlation was found with microcystic changes in the tumor tissue. This finding challenges the hypothesis that such microcystic changes and/or enlarged intercellular spaces in the tissue of these tumors are an important part of explaining the occurrence of the T2-FLAIR mismatch.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. van Maren EA, Dankbaar JW, Wesseling P, et al. T2-FLAIR Mismatch: An Imaging Biomarker for Children's MYB/MYBL1-Altered Diffuse Astrocytoma or Angiocentric Glioma. AJNR Am J Neuroradiol. 2024. PMID: 38724203. doi:10.3174/ajnr.A8203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。